Guo Wei, Shen Yue-Liang, Chen Ying-Ying, Hu Zhi-Bin, Yan Zhi-Kun, Xia Qiang
Department of Physiology, Zhejiang University School of Medicine, Hangzhou, China.
Sheng Li Xue Bao. 2004 Oct 25;56(5):632-8.
Prolongation of the duration of heart preservation in vitro is very important in clinical heart transplantation. Previous studies have shown that mitochondrial ATP-sensitive potassium channel (mitoK(ATP)) plays an important role in cardioprotective effect. The purpose of this study was to assess whether the mitoK(ATP) opener diazoxide as an additive to cardioplegia solution could enhance myocardial protection during long-term hypothermic preservation of the rat heart. Langendorff model of isolated rat heart was used. After 30 min stabilization of perfusion, the hearts were stored in Celsior cardioplegia solution at 4 degrees C with (15, 30 and 45 micromol/L) or without diazoxide, a mitoK(ATP) channel opener, for 10 h followed by 60 min reperfusion. The recovery of cardiac contractile function, myocardial enzyme leakage in the coronary effluent, and myocardial water content were determined. The myocardial ultrastructure was also observed. We found that: (1) Diazoxide treatment improved the recovery of left ventricular developed pressure and +/-dp/dt(max) dose-dependently. Left ventricular end-diastolic pressure was significantly lower in diazoxide-treated hearts than that of hearts in Celsior solution after hypothermic preservation for 10 h. (2) Diazoxide at 30 and 45 micromol/L significantly decreased the water content of myocardium and increased coronary flow of the hearts compared to those in control. (3) The leakage of myocardial enzymes (lactate dehydrogenase, creatine kinase and glutamate-oxaloacetate transaminase) in the coronary effluent was significantly reduced in diazoxide-treated hearts. (4) Impairment of myocardial ultrastructure after 10 h hypothermic preservation was alleviated in hearts treated with 30 micromol/L diazoxide. (5) The cardiac effects of 30 micromol/L diazoxide were attenuated by a mitoK(ATP) blocker 5-hydroxydecanoate (5-HD, 100 micromol/L). These results indicate that diazoxide as a supplementation in cardioplegia solution could enhance myocardial protection during long-term hypothermic heart preservation via opening of mitochondrial K(ATP) channel.
在临床心脏移植中,延长心脏体外保存时间非常重要。先前的研究表明,线粒体ATP敏感性钾通道(mitoK(ATP))在心脏保护作用中发挥重要作用。本研究的目的是评估mitoK(ATP)开放剂二氮嗪作为心脏停搏液添加剂,在大鼠心脏长期低温保存期间是否能增强心肌保护作用。采用离体大鼠心脏Langendorff模型。灌注稳定30分钟后,将心脏置于含(15、30和45微摩尔/升)或不含mitoK(ATP)通道开放剂二氮嗪的Celsior心脏停搏液中,于4℃保存10小时,随后再灌注60分钟。测定心脏收缩功能的恢复、冠状动脉流出液中心肌酶的泄漏以及心肌含水量。同时观察心肌超微结构。我们发现:(1)二氮嗪处理能剂量依赖性地改善左心室舒张末压和±dp/dt(max)的恢复。低温保存10小时后,二氮嗪处理组心脏的左心室舒张末压显著低于Celsior液组心脏。(2)与对照组相比,30和45微摩尔/升的二氮嗪显著降低了心肌含水量,并增加了心脏的冠状动脉血流量。(3)二氮嗪处理组心脏冠状动脉流出液中心肌酶(乳酸脱氢酶、肌酸激酶和谷草转氨酶)的泄漏显著减少。(4)30微摩尔/升二氮嗪处理的心脏在低温保存10小时后心肌超微结构的损伤得到缓解。(5)30微摩尔/升二氮嗪的心脏效应被mitoK(ATP)阻滞剂5-羟基癸酸(5-HD,100微摩尔/升)减弱。这些结果表明,二氮嗪作为心脏停搏液的补充剂,可通过开放线粒体K(ATP)通道增强心脏长期低温保存期间的心肌保护作用。